M&A

dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bnJPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn

Johnson & Johnson got the JP Morgan Healthcare Conference off to a flying start with its $14.6 billion Intra-Cellular Therapies buy.

byMillie Nelson, Editor
Jan 15, 2025
|
1 Min Read
JPM written on wooden blocks in blue
Investment
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRxJPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
byMillie Nelson
Jan 14, 2025
1 Min Read
2025 wooden blocks
Investment
Takeovers, Trump, and trends: how biopharma is likely to shift this yearTakeovers, Trump, and trends: how biopharma is shifting this year
byJonathan Smith
Jan 1, 2025
1 Min Read
Two cartoons pushing puzzle pieces together
Investment
Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75mChroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m
byMillie Nelson
Dec 23, 2024
1 Min Read
M&A on wooden blocks
Investment
AbbVie forks out $200m to buy Roche spin-out NimbleAbbVie forks out $200m to buy Roche spin-out Nimble
byMillie Nelson
Dec 19, 2024
1 Min Read
2024 on a road
Investment
Megadeals continued amid sluggish investments and M&A in 2024Megadeals continued amid sluggish investments and M&A in 2024
byJonathan Smith
Dec 18, 2024
1 Min Read
Currency
Investment
Eyes on Asia: Merck and BioNTech land Chinese bispecifics
Eyes on Asia: Merck and BioNTech land Chinese bispecifics
Dec 4, 2024
|
1 Min Read
byRichard Daverman, Editor
The ELA'S 2024
Innovation
LSX awards the crème de la crème of dealmaking
LSX awards the crème de la crème of dealmaking
Dec 3, 2024
|
1 Min Read
byMillie Nelson, Editor
M&A note
Investment
Novartis chases muscular dystrophy treatment with Kate Tx buy
Novartis chases muscular dystrophy treatment with Kate Tx buy
Nov 27, 2024
|
1 Min Read
byMillie Nelson, Editor
Reverse arrow
Partnering
Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange
Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange
Oct 31, 2024
|
1 Min Read
byRichard Daverman, Editor
Alzheimer's disease written in blocks
Partnering
AbbVie forks out $1.4bn to buy Alzheimer’s therapy developer Aliada
AbbVie forks out $1.4bn to buy Aliada
Oct 29, 2024
|
1 Min Read
byMillie Nelson, Editor
Wooden block with people icons
Partnering
Want to be a partner of choice? Distinguish yourself in the space
Want to be a partner of choice? Distinguish yourself in the space
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
Partnering
To be truly great you need to partner, says J&J
To be truly great you need to partner, says J&J
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
Christmas present
Partnering
RayzeBio: A Christmas to remember
RayzeBio: A Christmas to remember
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
People making business deals
Partnering
Prometheus and Merck: Under the bonnet of the largest pre-Phase III M&A deal
Under the bonnet of the largest pre-Phase III M&A deal
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
Partnering
Top five Asia biopharma deals: August 2024
Asia biopharma deals: August 2024
Sep 15, 2024
|
1 Min Read
byRichard Daverman, Editor

BIO-EUROPE COVERAGE

Novo Nordisk sign
Business Strategy
Lessons and blessings: The Novo Nordisk way
Lessons and blessings: The Novo Nordisk way
Michael May, PhD, President, CCRM discusses Canada as a place for life sciences in this video.
Hubs
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Shaking hands
Partnering
Picky pharma prone to better proven partners amid dealmaking downturn
Picky pharma prone to better proven partners amid dealmaking downturn
Hervé Ansanay, Biotech Alliance Manager, discusses the features of the RESEAU SATT - SATT NETWORK
Hubs
RESEAU SATT, the Best of French Deep Tech
RESEAU SATT, the Best of French Deep Tech
Jan 13 - Jan 15, 2025
An all-inclusive healthcare conference at Hilton Union Square, San Francisco
Register

Latest

Novo Nordisk logo on a window
Business Strategy
Novo on the ‘ins and outs’ of its nucleic acid growth
Novo on the ‘ins and outs’ of its nucleic acid growth
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM written on wooden blocks in blue
Investment
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.
Stay Updated